Tests bee venom injections for bone and mineral problems in kidney dialysis patients
Tests bee venom injections against standard care in adults on hemodialysis.
Plain-language title generated from the registry record
Registry title: Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 1/2
Where in Egypt
- Urology and Nephrology Center, Mansoura UniversityAl Mansurah, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mansoura University
- Trial code
- NCT06901102
- Record updated
- 28 March 2025
- Original description
This study aims to evaluate the effectiveness of bee venom injections as a treatment for chronic kidney disease (CKD)-mineral bone disorder (MBD) in patients undergoing hemodialysis. MBD is a common complication in CKD patients, leading to abnormal mineral metabolism, bone disease, and increased cardiovascular risks. Current treatments are often inadequate and can have significant side effects.Read full original descriptionShow less
Bee Venom As Immunomodulator and Its Effect on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Prospective Randomized Controlled Trial
This study aims to evaluate the effectiveness of bee venom injections as a treatment for chronic kidney disease (CKD)-mineral bone disorder (MBD) in patients undergoing hemodialysis. MBD is a common complication in CKD patients, leading to abnormal mineral metabolism, bone disease, and increased cardiovascular risks. Current treatments are often inadequate and can have significant side effects.
In this study, we will compare the effects of bee venom injections with standard care treatments in hemodialysis patients. Bee venom is known for its potential anti-inflammatory and immunomodulatory properties, which may help improve mineral metabolism and bone health regulation in these patients. By stimulating regulatory T cells (Tregs) through bee venom, we aim to reduce inflammation and restore bone health.
We hope to answer whether bee venom can effectively reduce mineral bone disorder markers (such as calcium, phosphorus, and parathyroid hormone levels) and improve bone density in hemodialysis patients. The results could lead to a new treatment option for CKD-MBD, improving patient outcomes and quality of life.
Inclusion: Patients of both sexes aged 18 years and older; Patients undergoing maintenance hemodialysis three times weekly for at least six months; Patients who are not scheduled for kidney transplantation within the next year.
Exclusion: Current use of medications affecting bone metabolism (e.g., calcitonin, denosumab, estrogen) within the last six months; Medical history of chronic conditions such as liver disease, cancer, or autoimmune diseases; Active chronic infections, including HIV, HCV, HBV, and tuberculosis; History of renal allograft failure within the past year; Current pregnancy or lactation; Refusal to participate in the study.